Epcoritamab
Relapsed/Refractory Large B-cell Lymphoma
Key Facts
About Genmab
Founded in 1999, Genmab's mission is to improve the lives of patients through innovative antibody therapeutics. The company has achieved remarkable success with its partnered assets, DARZALEX® and KESIMPTA®, which have become multi-billion dollar therapies, validating its scientific approach. Its strategy combines advancing a deep, wholly-owned clinical pipeline with high-value collaborations, funded by substantial royalty revenue. This hybrid model positions Genmab to sustainably capture value from both its platform innovation and direct drug development.
View full company profileAbout Genmab
Founded in 1999, Genmab's mission is to improve the lives of patients through innovative antibody therapeutics. The company has achieved remarkable success with its partnered assets, DARZALEX® and KESIMPTA®, which have become multi-billion dollar therapies, validating its scientific approach. Its strategy combines advancing a deep, wholly-owned clinical pipeline with high-value collaborations, funded by substantial royalty revenue. This hybrid model positions Genmab to sustainably capture value from both its platform innovation and direct drug development.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Large B-cell Lymphoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Yi Kai Da (Axicabtagene Ciloleucel) | Fosun Pharma | Approved |